Selexis SA?and?Teneobio, Inc.?have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs), a new class of multi-specific biologics. Teneobio will utilize Selexis’ SUREtechnology?Platform
Alvotech?and?Fuji Pharma?have entered an exclusive agreement for the development and commercialization of biosimilars in Japan. Fuji is acquiring a 4.2% stake in Alvotech for approximately $50 million